About Zymeworks Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.zymeworks.com/
Frequently Asked Questions
What is the 52-week range for ZYME?
The 52-week high is $31.34 and the 52-week low is $16.003.
What is the P/E ratio for ZYME?
The P/E ratio data is currently unavailable.
What is the dividend yield for ZYME?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -72.07%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -404.00%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 7.39.
Analyst Recommendation Trends
Wall Street analyst consensus for ZYME over the last few months:
Latest ZYME News
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
Zymeworks (NASDAQ:ZYME) said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax attributes and a commercial organization to its business. Management said the transaction represent
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $39
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $38 to $39.
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Inc. (ZYME) M&A Call September 28, 2026 8:30 AM EDTCompany ParticipantsShrinal Inamdar - Vice President of Investor RelationsScott Platshon -...
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assetsYUPELRI® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRRZymeworks to retain existing commercial organization supporting YUPELRI hospital promotionThe Company expects total revenue, including collaboration revenue from YUPELRI, for 2026 to be between $278 million and $292 mill
Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow
2026-09-28. The following slide deck was published by Zymeworks Inc.
Zymeworks Sees FY2026 Sales $278.000M-$292.000M vs $302.577M Est
Zymeworks (NASDAQ:ZYME) sees FY2026 sales of $278.000 million-$292.000 million vs $302.577 million analyst estimate.
Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M
Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final
Zymeworks Completes Acquisition of Theravance Biopharma
Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks,
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Zii
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow
Zymeworks Inc. remains a Buy, leveraging validated technology, strong price momentum, and upcoming catalysts. Read more on ZYME stock here.
Wolfe Research Initiates Coverage On Zymeworks with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Zymeworks (NASDAQ:ZYME) with a Outperform rating.
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zymeworks Inc. (ZYME) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:50 PM EDTCompany ParticipantsKenneth Galbraith - Chairman...
JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33
JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $31 to $33.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-06 | Hollywood Mark | +939 | $22.22 | $20,865 |
| 2026-05-13 | Schneider Paul R | +119,000 | - | - |
| 2026-05-13 | Schneider Paul R | +178,000 | - | - |
| 2026-04-09 | Schayowitz Adam | +76,000 | - | - |
| 2026-04-09 | Schayowitz Adam | +47,000 | - | - |
| 2026-04-09 | Schayowitz Adam | +70,000 | - | - |
| 2026-04-09 | Platshon Scott | +76,000 | - | - |
| 2026-04-09 | Platshon Scott | +47,000 | - | - |
| 2026-04-09 | Platshon Scott | +70,000 | - | - |
| 2026-04-06 | Stafford Kristin | +50,000 | - | - |
| 2026-04-06 | Stafford Kristin | +119,000 | - | - |
| 2026-04-06 | Stafford Kristin | +178,000 | - | - |
| 2026-01-12 | Hollywood Mark | +66,000 | - | - |
| 2026-01-12 | Hollywood Mark | +47,000 | - | - |
| 2026-01-12 | Hollywood Mark | +70,000 | - | - |
| 2026-01-12 | Hollywood Mark | -17,666 | - | - |
| 2026-01-12 | Hollywood Mark | -6,120 | $22.6735 | $138,762 |
| 2026-01-12 | Hollywood Mark | +17,666 | - | - |
| 2026-01-12 | Cherry Brian N | +15,400 | - | - |
| 2026-01-12 | Cherry Brian N | +23,000 | - | - |
| 2026-01-12 | Ciongoli Gregory Austin | +7,700 | - | - |
| 2026-01-12 | Ciongoli Gregory Austin | +11,500 | - | - |
| 2026-01-12 | Moore Paul Andrew | +66,000 | - | - |
| 2026-01-12 | Moore Paul Andrew | +47,000 | - | - |
| 2026-01-12 | Moore Paul Andrew | +70,000 | - | - |
| 2026-01-12 | Moore Paul Andrew | -17,666 | - | - |
| 2026-01-12 | Moore Paul Andrew | -9,560 | $22.6735 | $216,759 |
| 2026-01-12 | Moore Paul Andrew | +17,666 | - | - |
| 2026-01-12 | Cesano Alessandra | +7,700 | - | - |
| 2026-01-12 | Cesano Alessandra | +11,500 | - | - |
| 2026-01-12 | Campoy Carlos | +7,700 | - | - |
| 2026-01-12 | Campoy Carlos | +11,500 | - | - |
| 2026-01-12 | Smith Jeffrey T L | -17,666 | - | - |
| 2026-01-12 | Smith Jeffrey T L | -9,310 | $22.6735 | $211,090 |
| 2026-01-12 | Smith Jeffrey T L | +17,666 | - | - |
| 2026-01-12 | Landry Robert E | +7,700 | - | - |
| 2026-01-12 | Landry Robert E | +11,500 | - | - |
| 2026-01-12 | Galbraith Kenneth | +222,000 | - | - |
| 2026-01-12 | Galbraith Kenneth | +144,000 | - | - |
| 2026-01-12 | Galbraith Kenneth | +216,000 | - | - |
| 2026-01-12 | Galbraith Kenneth | -64,000 | - | - |
| 2026-01-12 | Galbraith Kenneth | -30,424 | $22.6735 | $689,819 |
| 2026-01-12 | Galbraith Kenneth | +64,000 | - | - |
| 2026-01-12 | Neu Kelvin | +7,700 | - | - |
| 2026-01-12 | Neu Kelvin | +11,500 | - | - |
| 2026-01-12 | Mahony Susan | +7,700 | - | - |
| 2026-01-12 | Mahony Susan | +11,500 | - | - |
| 2026-01-06 | PATTERSON LEONE D | +459 | $10.55 | $4,842 |
| 2026-01-05 | Moore Paul Andrew | -20,000 | - | - |
| 2026-01-05 | Moore Paul Andrew | -17,168 | - | - |
| 2026-01-05 | Moore Paul Andrew | -10,821 | $25.0969 | $271,574 |
| 2026-01-05 | Moore Paul Andrew | +20,000 | - | - |
| 2026-01-05 | Moore Paul Andrew | -9,289 | $25.0969 | $233,125 |
| 2026-01-05 | Moore Paul Andrew | +17,168 | - | - |
| 2026-01-05 | Smith Jeffrey T L | -20,000 | - | - |
| 2026-01-05 | Smith Jeffrey T L | -10,538 | $25.0969 | $264,471 |
| 2026-01-05 | Smith Jeffrey T L | +20,000 | - | - |
| 2026-01-05 | Galbraith Kenneth | -66,666 | - | - |
| 2026-01-05 | Galbraith Kenneth | -47,668 | - | - |
| 2026-01-05 | Galbraith Kenneth | -31,686 | $25.0969 | $795,220 |
| 2026-01-05 | Galbraith Kenneth | +66,666 | - | - |
| 2026-01-05 | Galbraith Kenneth | -22,657 | $25.0969 | $568,620 |
| 2026-01-05 | Galbraith Kenneth | +47,668 | - | - |
| 2025-12-22 | Galbraith Kenneth | -100,000 | - | - |
| 2025-12-22 | Galbraith Kenneth | -47,528 | $27.0222 | $1,284,311 |
| 2025-12-22 | Galbraith Kenneth | +100,000 | - | - |